Hydroxyethyl starch 200/0.5 decreases circulating tumor cells of colorectal cancer patients and reduces metastatic potential of colon cancer cell line through inhibiting platelets activation
详细信息 查看全文
- 作者：Hua Liang ; Chengxiang Yang ; Bin Zhang ; Hanbing Wang ; Hongzhen Liu…
- 关键词：Hydroxyethyl starch ; Circulating tumor cells ; Platelets ; Colorectal cancer
- 刊名：Medical Oncology
- 出版年：2015
- 出版时间：May 2015
- 年：2015
- 卷：32
- 期：5
- 全文大小：1,242 KB
- 参考文献：1. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics for hispanics/latinos, 2012. CA Cancer J Clin 62: pp. 283-298 CrossRef
2. Sample, CB, Watson, M, Okrainec, A (2006) Long-term outcomes of laparoscopic surgery for colorectal cancer. Surg Endosc 20: pp. 30-34 CrossRef
3. Li, C, Cai, S, Wang, X, Jiang, Z (2014) Hypomethylation-associated up-regulation of TCF3 expression and recurrence in stage II and III colorectal cancer. PLoS One 9: pp. e112005 CrossRef
4. Zhang, W, Song, T (2014) The progress in adjuvant therapy after curative resection of liver metastasis from colorectal cancer. Drug Discov Ther 8: pp. 194-200 CrossRef
5. Neeman, E, Ben-Eliyahu, S (2013) Surgery and stress promote cancer metastasis: new outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun 30: pp. S32-S40 CrossRef
6. Exadaktylos, AK, Buggy, DJ, Moriarty, DC (2006) Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?. Anesthesiology 105: pp. 660-664 CrossRef
7. Klein, CA (2009) Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: pp. 302-312 CrossRef
8. Goldfarb, Y, Sorski, L, Benish, M (2011) Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 253: pp. 798-810 CrossRef
9. Benish, M, Bartal, I, Goldfarb, Y (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15: pp. 2042-2052 CrossRef
10. Kin, C, Kidess, E, Poultsides, GA (2013) Colorectal cancer diagnostics: biomarkers, cell-free DNA, circulating tumor cells and defining heterogeneous populations by single-cell analysis. E Expert Rev Mol Diagn 13: pp. 581-599 CrossRef
11. Kuboki, Y, Matsusaka, S, Minowa, S (2013) Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res 33: pp. 3905-3910
12. Peach, G, Kim, C, Zacharakis, E (2010) Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review. Br J Cancer 102: pp. 1327-1334 CrossRef
13. Groot Koerkamp, B, Rahbari, NN, Buchler, MW (2013) Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol 20: pp. 2156-2165 CrossRef
14. Lagoudianakis, EE, Kataki, A, Manouras, A (2009) Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res 155: pp. 183-190 CrossRef
15. Palumbo, JS (2008) Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 34: pp. 154-160 CrossRef
16. Thorson, CM, Haren, RM, Ryan, ML (2014) Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 155: pp. 134-144
文摘
Platelets play an important role in metastasis of circulating tumor cells (CTCs). It has been demonstrated that hydroxyethyl starch (HES) inhibits platelets function. However, the effect of HES on CTCs in patients with colorectal cancer remains unclear. We compared the effects of HES 200/0.5 and HES 130/0.4 on CTCs and platelets activation of colorectal patients in this study. Additionally, the effects of HES 200/0.5 or HES 130/0.4 on metastasis ability of colon cancer cell line that stimulated by activated platelets have been explored. In vivo, 90 patients undergoing colorectal cancer radical surgery received randomly 15?mL/kg of HES 200/0.5 (n?=?45) or HES 130/0.4 (n?=?45) infusion before surgery. Platelet glycoprotein IIb/IIIa (GPIIb/IIIa), CD62P and platelets aggregation rate (PAR) were evaluated pre-, intra- and postoperatively. Cytokeratin-20 (CK-20) mRNA was detected by reverse transcriptase polymerase chain reaction before and after surgery. In vitro, colon cancer SW480 cells were incubated with activated platelets in the presence or absence HES 200/0.5 or HES 130/0.4. The metastasis ability of SW480 cells was assessed by Transwell assay. The results showed that CK-20 mRNA positive rate in HES 200/0.5 group after surgery was decreased significantly as compared to group HES 130/0.4 (χ 2?=?6.164, P?=?0.013). Simultaneously, a more pronounced inhibition of platelets activation was observed in group HES 200/0.5. A positive correlation between platelets activation marker and CK-20 mRNA positive rate was found. In vitro, HES 200/0.5, but not HES 130/0.4, decreased the invasion and migration ability of SW480 cells that induced by activated platelets. Besides, the expression of GPIIb/IIIa, CD62P and PAR was inhibited more strongly in group HES 200/0.5 than those in group HES 130/0.4. In summary, we found that HES 200/0.5 significantly decreased CTCs of patients undergoing colorectal cancer radical surgery as compared to HES 130/0.4, which might be associated with inhibiting platelets activation of HES 200/0.5. Furthermore, HES 200/0.5, but not HES 130/0.4, reduced the metastatic potential of colon cell line stimulated by activated platelets through depressing platelets activation. Modulation of platelets activity may be a novel strategy to minimize the risk of metastasis during surgery.